Pharmacodynamics<unk>  is "an estrogen agonist/antagonist that makes vaginal tissue thicker and less fragile resulting in a reduction in the amount of pain women experience with sexual intercourse." This medication should be used for the shortest amount of time possible due to associated adverse effects.<unk>  might not have an adverse influence on coagulation, in contrast to estrogens and other SERMs like tamoxifen and raloxifene. A binding assay was also performed to measure the affinity of<unk>  for the estrogen receptor (ERα and ERβ). The study showed that<unk>  bound ERα and ERβ with similar affinity.<unk>  bound the estrogen receptors with a lower affinity than estradiol.<unk>  was shown to be an antagonist of "ERE-mediated transactivation on MCF-7 cells," which the authors concluded indicates "anti-estrogenic activity in breast cancer cells." Pharmacokinetics The pharmacokinetics of<unk>  were dose-dependent over a dose range of 10 to 800 mg/day.
Ospemifene
Veristrat
Sesquimustard
Acolbifene
Toremifene
Tiotixene
Patiromer
Mitapivat